密迪斯肌(08307) - 2025 - 年度财报

Company Information This report details the company's core information, including board members, committee structures, legal advisors, principal bankers, registered office, and share registrar Chairman's Statement The Chairman's Statement outlines the company's strategic response to a challenging market, focusing on cost-saving, favorable leasing, and future AI integration for precise skincare - Facing challenges from slow Hong Kong economic recovery, rising interest rates, and changing consumer habits (e.g., increased cross-border spending), the company implemented cost-saving measures and optimized operational processes[8] - The company capitalized on the downturn in the real estate market to secure more favorable leasing terms for its medical skincare centers and office spaces, aiming to reduce future costs[8] - Future strategic priorities include deepening market penetration, focusing on anti-aging and preventive care, and evaluating the integration of Artificial Intelligence (AI) technology into services to provide data-driven skincare solutions[10] Management Discussion and Analysis This section analyzes the Group's performance in a challenging macroeconomic environment, detailing financial results, strategic responses, liquidity, identified risks, and future outlook Business Review This section reviews the Group's business as a Hong Kong medical skincare provider, detailing its performance amidst macroeconomic challenges and competitive pressures, and highlighting strategic responses like new technology introduction 2025 Key Performance Indicators | Metric | FY2025 (million HKD) | FY2024 (million HKD) | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | 45.1 | 49.1 | -8.2% | | Loss Attributable to Owners of the Company | 3.4 | 3.0 | +10.8% | | Basic Loss Per Share (HK cents) | 0.85 | 0.77 | +10.4% | - The Group's revenue primarily derives from three segments: treatment services accounting for 78.7%, prescription and dispensing services for 19.0%, and medical consultation services for 2.3%[16] - To maintain competitiveness, the Group introduced the popular "Titanium Lift" laser treatment technology from Korea during the review year, which uses three laser wavelengths to stimulate deep collagen regeneration and improve skin firmness[14] Financial Review For the current fiscal year, the Group's revenue decreased by 8.2% to HKD 45.1 million due to cautious consumer spending and increased industry competition, with net other income rising by 78.9% to HKD 1.8 million from reversal of restoration cost provisions and increased bank interest income, ultimately expanding loss attributable to owners to HKD 3.4 million 2025 Financial Performance Summary (Year-on-Year Change) | Financial Item | FY2025 (million HKD) | FY2024 (million HKD) | Reason for Change | | :--- | :--- | :--- | :--- | | Revenue | 45.1 | 49.1 | Decrease in customer numbers and visits | | Other Income, Gains and Losses | 1.8 | 1.0 | Reversal of restoration cost provisions and increase in interest income | | Inventories Used | 8.5 | 9.7 | Decreased in line with revenue | | Staff Costs | 23.9 | 24.6 | Decrease in directors' emoluments and performance bonuses | | Other Expenses | 8.2 | 9.0 | Consistent with revenue decrease | | Loss for the Year | 3.4 | 3.0 | Impact of revenue decrease outweighed benefits of cost control | - The Board did not recommend the payment of a final dividend for the year ended March 31, 2025[28] Capital Structure, Liquidity and Financial Resources As of March 31, 2025, the Group's total equity was HKD 4.2 million, with bank balances and cash at HKD 17.3 million, and despite a net current liability of HKD 6.2 million, the Group possesses sufficient financial resources, including HKD 9 million in bank borrowings and HKD 18 million in undrawn bank facilities, to support future operations, while the gearing ratio significantly increased from 14.4% to 39.7% Capital and Liquidity Position (as of March 31, 2025) | Metric | 2025 (million HKD) | 2024 (million HKD) | | :--- | :--- | :--- | | Total Equity | 4.2 | 7.6 | | Bank Balances and Cash | 17.3 | 6.9 | | Pledged Bank Deposits | 13.9 | 13.9 | | Net Current Liabilities | (6.2) | (2.1) | | Bank Borrowings | 9.0 | 0 | | Undrawn Bank Facilities | 18.0 | 18.0 | | Gearing Ratio | 39.7% | 14.4% | - The Group's net current liabilities primarily stem from contract liabilities (prepaid treatment packages), which ultimately do not result in cash outflows[46] Key Risks and Uncertainties The Group faces key risks across business, industry, regulatory, economic, reputational, and financial dimensions, including reliance on key registered medical practitioners, intense industry competition, potential regulatory changes, economic fluctuations impacting consumer spending, and service quality-related reputational risks, alongside managing credit, liquidity, foreign exchange, and interest rate risks - Business Risk: High reliance on attracting and retaining skilled registered medical practitioners, with limited suitable talent and intense competition in the market[39] - Industry and Economic Risks: The medical skincare industry is sensitive to negative publicity, with volatile market trends and fierce competition, and an economic downturn could lead to reduced customer spending on medical aesthetic services[40][42] - Financial Risks: Primarily include customer credit risk, liquidity risk due to high contract liabilities, foreign exchange risk related to USD and RMB, and interest rate risk associated with floating-rate bank deposits and borrowings[45][46][47][48] Employees and Remuneration Policy As of March 31, 2025, the Group employed 43 staff members (27 full-time, 16 part-time), with annual staff costs of HKD 23.9 million, and remuneration is determined based on market levels, individual performance, and responsibilities, with a new share option scheme adopted on September 27, 2024, to incentivize and retain talent Staff Profile | Metric | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Full-time Employees | 27 | 29 | | Part-time Employees | 16 | 14 | | Total Employees | 43 | 43 | | Staff Costs (million HKD) | 23.9 | 24.6 | - The company adopted a new share option scheme on September 27, 2024, to incentivize and retain eligible employees[49] Directors' Report This report outlines the Group's business operations, financial position, and corporate governance matters for the year ended March 31, 2025, with the Group primarily engaged in investment holding and its subsidiaries in medical skincare services, confirming compliance with relevant laws, no purchases, sales, or redemptions of listed securities, and sufficient public float, while detailing directors' and substantial shareholders' interests, including Chairman Dr. Kong Kwok Leung's 69.28% stake, and explaining the new share option scheme adopted in September 2024, with the Audit Committee having reviewed the annual financial statements Principal Business and Compliance The Company is an investment holding company, with its subsidiaries primarily engaged in medical skincare services, and during the reporting period, the Group complied in all material respects with laws and regulations significantly affecting its business, while committing to environmental protection and maintaining good relationships with stakeholders - The Company is an investment holding company, with details of its subsidiaries' principal businesses provided in Note 34 to the consolidated financial statements[51] - During the review year, the Group complied in all material respects with relevant laws and regulations significantly affecting its business and operations, with no serious violations occurring[53] Disclosure of Interests As of March 31, 2025, Chairman Dr. Kong Kwok Leung beneficially held 274,865,400 shares, representing 69.28% of the issued share capital, through his wholly-owned company Topline Worldwide Limited, with no other directors, chief executives, or substantial shareholders holding disclosable interests or short positions Major Shareholder Interests (as of March 31, 2025) | Shareholder Name | Capacity/Nature of Interest | Number of Shares Held | % of Issued Share Capital | | :--- | :--- | :--- | :--- | | Dr. Kong Kwok Leung | Interest of controlled corporation | 274,865,400 | 69.28% | | Topline Worldwide Limited | Beneficial owner | 274,865,400 | 69.28% | Share Option Scheme The company terminated its old share option scheme and adopted a new 10-year scheme on September 27, 2024, aimed at attracting and incentivizing talent, with a maximum of 39,673,600 shares (representing 10% of issued shares at adoption date) available for grant, and detailed provisions for eligible participants, grant limits, exercise price, and vesting periods, while no share options were granted, exercised, or cancelled under either scheme as of March 31, 2025, with no outstanding options - The company adopted a new share option scheme on September 27, 2024, replacing the old scheme terminated on the same day[83] - The maximum number of share options that may be granted under the new scheme is 39,673,600 shares, equivalent to 10% of the issued shares on the adoption date[86] - For the year ended March 31, 2025, no share options were granted, exercised, vested, lapsed, or cancelled by the company, and there were no outstanding share options[94] Corporate Governance Report This report details the company's corporate governance practices for the year ended March 31, 2025, confirming compliance with most GEM Listing Rules' Corporate Governance Code provisions, with one deviation noted where the Chairman and CEO roles are held by the same individual, Dr. Kong Kwok Leung, which the Board believes enhances strategy execution and efficiency, while also outlining the Board's composition, responsibilities, meeting attendance, and the operations of its Audit, Remuneration, and Nomination Committees, alongside governance measures for director training, financial reporting, internal control, risk management, and shareholder communication Board of Directors The Board of Directors, comprising four executive and three independent non-executive directors, is responsible for leading and overseeing Group affairs, held four meetings during the reporting period with full attendance by all directors, and despite the Chairman and CEO roles being combined in Dr. Kong Kwok Leung, a deviation from the Corporate Governance Code, the Board believes this structure does not undermine power balance and enhances operational efficiency, with the Board collectively responsible for corporate governance functions - The roles of Chairman and Chief Executive Officer are held by Dr. Kong Kwok Leung, a deviation from Code Provision C.2.1 of the Corporate Governance Code, which the Board believes facilitates strategy implementation and enhances operational efficiency[117] - During the review year, the Board held 4 meetings, with all directors attending all meetings[113] - The Board is collectively responsible for corporate governance duties, including formulating and reviewing corporate governance policies, monitoring director training, and legal compliance[116] Board Committees The Board has three committees: Audit, Remuneration, and Nomination, with the Audit Committee, composed of three independent non-executive directors, overseeing financial reporting and internal controls; the Remuneration Committee reviewing compensation policies; and the Nomination Committee handling director nominations and evaluations, all operating under written terms of reference and holding meetings during the year, while the company has also adopted a Board Diversity Policy, with three female directors currently comprising 43% of the Board - The Audit Committee, composed of three independent non-executive directors, held three meetings during the year, reviewing annual/interim results, risk assessment reports, and evaluating the effectiveness of internal control systems[126] - The Remuneration Committee, composed of two executive directors and three independent non-executive directors, held one meeting during the year, providing recommendations to the Board on remuneration policies for directors and senior management[128] - The Nomination Committee, composed of two executive directors and three independent non-executive directors, held one meeting during the year, reviewing the Board structure, assessing the independence of independent non-executive directors, and making recommendations for director re-election[129][130] - The company has adopted a Board Diversity Policy, with three female members currently comprising 43% of the seven-member Board[135] Accountability and Audit The Board is responsible for overseeing the preparation of financial statements to ensure their true and fair presentation, and the Group has appointed Shinewing Risk Management Limited as its internal auditor to conduct annual reviews of risk management and internal control systems, which the Audit Committee deems adequate and effective, with total audit and non-audit service fees paid to external auditor Grant Thornton Hong Kong Limited amounting to HKD 420,000 during the reporting period - The Board is responsible for maintaining sound and effective internal control systems, and external internal auditor Shinewing Risk Management has reviewed the Group's risk management and internal control systems, deeming them adequate and effective[139][141] Auditor's Remuneration (For the Year Ended March 31, 2025) | Service Type | Amount (thousand HKD) | | :--- | :--- | | Audit Services | 410 | | Non-audit Services (Review of preliminary results announcement) | 10 | | Total | 420 | Shareholder Rights and Communication The company has established a shareholder communication policy, maintaining engagement through various channels including annual reports, announcements, general meetings, and the company website, clearly outlining shareholders' rights and procedures for convening extraordinary general meetings, submitting inquiries to the Board, proposing resolutions at general meetings, and nominating directors, while also adopting a dividend policy where dividend declaration will be at the Board's discretion based on earnings, financial position, and other factors - Shareholders holding not less than one-tenth of the company's paid-up share capital have the right to request the Board to convene an extraordinary general meeting[150] - The company has adopted a dividend policy, where the declaration and amount of dividends are at the Board's discretion, considering factors such as the Group's earnings, financial position, and funding needs[156] Environmental, Social and Governance Report This report details the Group's Environmental, Social, and Governance (ESG) performance and strategies, highlighting a year-on-year decrease in total greenhouse gas emissions with new reduction targets set, an emphasis on employee well-being, health and safety, and professional development with 279 hours of staff training and low turnover, strict adherence to product quality and client data privacy in operations, implementation of a stringent anti-corruption policy with training for nearly 70% of employees, and active community investment supporting charities, all overseen by the Board as a crucial component of long-term development Environmental Aspects The Group is committed to environmental protection, focusing on emissions, resource consumption, and waste management, with total greenhouse gas emissions decreasing from 50,636 kg CO2e to 48,045 kg CO2e during the reporting period, achieving its non-hazardous waste reduction target but missing its energy consumption density target, leading to new three-year reduction goals to cumulatively decrease Scope 1 and 2 emissions by 1% between 2026 and 2028, while medical waste management strictly complies with regulations and remains stable Greenhouse Gas Emissions (kg CO2e) | GHG Emission Source | 2025 | 2024 | | :--- | :--- | :--- | | Scope 1 (Direct Emissions) | 7,060 | 6,807 | | Scope 2 (Indirect Emissions) | 40,256 | 43,181 | | Scope 3 (Other Indirect Emissions) | 729 | 648 | | Total | 48,045 | 50,636 | Energy Consumption (kWh) | Energy Type | 2025 (kWh) | 2024 (kWh) | | :--- | :--- | :--- | | Petrol | 28,992 | 27,954 | | Purchased Electricity | 64,127 | 66,663 | | Total | 93,119 | 94,617 | - During the reporting period, the Group generated approximately 43 kg of medical waste and 4.7 tonnes of non-hazardous waste[181][184] - The Group set new targets to cumulatively reduce Scope 1 and 2 emissions by 1% and non-hazardous waste density by 3% between 2026 and 2028, both using 2023 as the base year[180][186] Social Aspects On the social front, the Group prioritizes employee development and well-being, health and safety, supply chain management, product responsibility, anti-corruption, and community investment, with 43 employees and an overall turnover rate of 14% at the end of the reporting period, providing 279 hours of staff training during the year, strictly adhering to labor standards by prohibiting child and forced labor, ensuring the safety and quality of pharmaceuticals and services with a customer complaint handling mechanism, maintaining a zero-tolerance stance on corruption with anti-corruption training for nearly 70% of employees, and actively participating in community charitable activities Employee Data (FY2025) | Metric | Data | | :--- | :--- | | Total Employees | 43 people | | Employee Turnover Rate | 14% | | Total Training Hours | 279.0 hours | | Lost Days Due to Work Injury | 2 days | - The Group offers competitive remuneration and benefits to employees and has established a new share option scheme to incentivize staff[202] - The Group maintains a zero-tolerance stance on corruption, providing anti-corruption training to nearly 70% of its employees during the year[232] - The Group actively engages in community investment, supporting organizations such as the Children's Cancer Foundation, Jing Yuan Charitable Foundation, and The Society of Rehabilitation and Crime Prevention of Hong Kong through donations and in-kind sponsorships totaling over HKD 38,000[237][238] Biographical Details of Directors and Senior Management This section provides detailed biographical information for the company's executive directors, independent non-executive directors, company secretary, and senior management, including their age, position, professional qualifications, industry experience, and roles in other listed companies, with Dr. Kong Kwok Leung, the Group's founder, Chairman, and CEO, possessing over 29 years of experience in the medical skincare industry - Dr. Kong Kwok Leung, 71 years old, is the Group's founder, Chairman, and Chief Executive Officer, with over 29 years of medical practice experience in the medical skincare services industry[239] - Familial relationships exist among Board members: Executive Director Ms. Tsui Kan is Dr. Kong Kwok Leung's cohabiting partner, and Executive Director Ms. Kong Chung Wai is Dr. Kong's niece[239][240] - Several directors and senior executives possess professional backgrounds in accounting and law, and hold directorships in other listed companies, demonstrating extensive professional knowledge and management experience[240][241][242] Independent Auditor's Report Independent Auditor Grant Thornton Hong Kong Limited issued an unmodified opinion on the Group's consolidated financial statements for the year ended March 31, 2025, affirming that the statements present a true and fair view of the Group's financial position, performance, and cash flows in compliance with Hong Kong Financial Reporting Standards and the Companies Ordinance's disclosure requirements, with "Revenue Recognition from Provision of Treatment Services" highlighted as a key audit matter due to the inherent risk of management manipulation to achieve specific targets - The auditor issued an unmodified opinion on the consolidated financial statements, deeming them to present a true and fair view of the Group's financial position and operating results[245] - "Revenue recognition from provision of treatment services" was identified as a key audit matter because revenue is a critical performance indicator for the Group, and there is an inherent risk of management manipulating the timing of revenue recognition to achieve targets[248] - For the key audit matter, the auditor performed various procedures, including understanding and evaluating relevant internal controls, sampling to verify revenue accuracy, and assessing the appropriateness of revenue recognition for expired unused prepaid treatment packages[249] Consolidated Financial Statements This section contains the Group's core financial statements for the year ended March 31, 2025, with the Consolidated Statement of Profit or Loss showing annual revenue of HKD 45.1 million and a loss for the year of HKD 3.38 million, the Consolidated Statement of Financial Position indicating total assets of HKD 57.44 million, total liabilities of HKD 53.25 million, net assets of HKD 4.20 million, and net current liabilities of HKD 6.17 million, and the Consolidated Statement of Cash Flows reporting net cash generated from operating activities of HKD 9.13 million, net cash inflow from financing activities of HKD 1.48 million, and an increase in cash and cash equivalents to HKD 17.34 million at year-end Consolidated Statement of Profit or Loss and Other Comprehensive Income For the year ended March 31, 2025, the Group's revenue was HKD 45.108 million, a decrease from HKD 49.135 million in the prior year, with the loss for the year expanding to HKD 3.382 million from HKD 3.102 million, and basic loss per share at HKD 0.85 cents Consolidated Statement of Profit or Loss Summary | Metric (thousand HKD) | 2025 | 2024 | | :--- | :--- | :--- | | Revenue | 45,108 | 49,135 | | Loss Before Tax | (3,463) | (3,124) | | Loss for the Year | (3,382) | (3,102) | | Loss Attributable to Owners of the Company | (3,377) | (3,048) | | Basic Loss Per Share (HK cents) | (0.85) | (0.77) | Consolidated Statement of Financial Position As of March 31, 2025, the Group's total assets were HKD 57.443 million, with non-current assets accounting for HKD 20.298 million, total liabilities at HKD 53.248 million, resulting in net assets of HKD 4.195 million, and notably, the Group had net current liabilities of HKD 6.168 million, primarily composed of HKD 25.359 million in contract liabilities (prepayments) Consolidated Statement of Financial Position Summary | Metric (thousand HKD) | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Assets | | | | Non-current Assets | 20,298 | 10,411 | | Current Assets | 37,145 | 29,649 | | Total Assets | 57,443 | 40,060 | | Liabilities and Equity | | | | Current Liabilities | 43,313 | 31,740 | | Non-current Liabilities | 9,935 | 739 | | Total Liabilities | 53,248 | 32,479 | | Net Assets | 4,195 | 7,581 | Consolidated Statement of Changes in Equity As of March 31, 2025, equity attributable to owners of the company decreased from HKD 10.95 million at the beginning of the year to HKD 4.195 million, primarily due to a loss for the year of HKD 3.377 million and an equity adjustment of HKD 3.374 million from the acquisition of additional equity interest in a non-wholly owned subsidiary, which also resulted in non-controlling interests being eliminated - Equity attributable to owners of the company decreased from HKD 10,950 thousand at the beginning of the year to HKD 4,195 thousand at year-end[261] - The decrease in equity is primarily attributed to a loss for the year of HKD 3,377 thousand and the accounting treatment for the acquisition of additional equity interest in a non-wholly owned subsidiary[261] Consolidated Statement of Cash Flows For the year ended March 31, 2025, the Group generated net cash of HKD 9.132 million from operating activities, with net cash outflow from investing activities of HKD 0.191 million primarily for property, plant, and equipment purchases, and net cash inflow from financing activities of HKD 1.478 million, mainly from new bank borrowings of HKD 9 million partially offset by lease liability repayments, resulting in a significant increase in cash and cash equivalents to HKD 17.344 million at year-end from HKD 6.927 million at the beginning of the year Consolidated Statement of Cash Flows Summary | Metric (thousand HKD) | 2025 | 2024 | | :--- | :--- | :--- | | Net Cash Generated from Operating Activities | 9,132 | 10,516 | | Net Cash Used in Investing Activities | (191) | (1,397) | | Net Cash Generated from (Used in) Financing Activities | 1,478 | (7,210) | | Net Increase in Cash and Cash Equivalents | 10,419 | 1,909 | | Cash and Cash Equivalents at Year-End | 17,344 | 6,927 | Notes to the Consolidated Financial Statements This section provides detailed explanations and supplementary information for the financial statements, disclosing the Group's significant accounting policies, including revenue recognition, leases, and financial instruments, with key information points such as revenue primarily from treatment services recognized over time, new bank borrowings of HKD 9 million during the year, an increase in contract liabilities (prepaid treatment packages) to HKD 25.36 million, and the acquisition of the remaining 49% equity interest in non-wholly owned subsidiary Rightway Honour on October 1, 2024, making it a wholly-owned subsidiary, with directors affirming the Group's ability to continue as a going concern despite net current liabilities Note 3 Summary of Significant Accounting Policies This note outlines the principal accounting policies used in preparing the consolidated financial statements, where despite net current liabilities of HKD 6.168 million as of March 31, 2025, directors consider the Group to have sufficient financial resources, including undrawn bank facilities, to continue as a going concern, with revenue from treatment services recognized over time using the output method, and revenue from prescription and dispensing services recognized at the point control of goods transfers to the customer, while lease accounting follows HKFRS 16, recognizing right-of-use assets and lease liabilities, and financial instruments are classified and measured under HKFRS 9, with impairment assessed using the expected credit loss model - Despite net current liabilities, considering operating cash flows and undrawn bank facilities, directors deem it appropriate to prepare financial statements on a going concern basis[270][273] - Revenue from treatment services is recognized over time using the output method, while revenue from prescription and dispensing services is recognized at the point control of goods transfers to the customer[285] - The Group applies the simplified approach to trade receivables, measuring loss allowances at an amount equal to lifetime expected credit losses[326] Note 5 Revenue For the current year, the Group's total revenue was HKD 45.108 million, with treatment services contributing the largest portion at HKD 35.52 million, followed by prescription and dispensing services at HKD 8.553 million, and medical consultation services at HKD 1.035 million, while future revenue expected to be recognized from contracts signed but unfulfilled (primarily prepaid treatments) amounted to HKD 25.359 million at the end of the reporting period Revenue Composition (thousand HKD) | Service Type | 2025 (thousand HKD) | 2024 (thousand HKD) | | :--- | :--- | :--- | | Medical Consultation Services | 1,035 | 1,121 | | Prescription and Dispensing Services | 8,553 | 9,439 | | Treatment Services | 35,520 | 38,575 | | Total | 45,108 | 49,135 | Note 23 Bank Borrowings As of March 31, 2025, the Group had HKD 9 million in unsecured bank borrowings, obtained under the SME Financing Guarantee Scheme and personally guaranteed by Chairman Dr. Kong and the Mortgage Corporation, with a 10-year repayment period and a floating interest rate, and despite the loan agreement containing a repayment on demand clause, directors believe the likelihood of the bank exercising this right is low - As of March 31, 2025, the Group had HKD 9,000,000 in bank borrowings, compared to zero in the prior year[382] - This borrowing is unsecured, obtained under the SME Financing Guarantee Scheme, and guaranteed by the controlling shareholder Dr. Kong and the Mortgage Corporation[383] Note 35 Acquisition of Additional Equity Interest in a Non-wholly Owned Subsidiary On October 1, 2024, the Group acquired the remaining 49% equity interest in its non-wholly owned subsidiary Rightway Honour for a total consideration of USD 2, making it a wholly-owned subsidiary, with this transaction accounted for as an equity transaction, resulting in a decrease of HKD 3.374 million in equity attributable to owners of the company and the elimination of non-controlling interests - On October 1, 2024, the Group acquired the remaining 49% equity interest in Rightway Honour and its subsidiaries, making it an indirectly wholly-owned subsidiary[427] - This acquisition was accounted for as an equity transaction, resulting in a decrease of HKD 3,374 thousand in equity attributable to owners of the company[427] Financial Summary This section provides a summary of the Group's results, assets, and liabilities for the past five fiscal years, indicating fluctuating revenue and losses recorded in the most recent three fiscal years, with total assets and total equity showing a continuous downward trend over the past five years Five-Year Financial Summary (thousand HKD) | For the Year Ended March 31 | 2025 | 2024 | 2023 | 2022 | 2021 | | :--- | :--- | :--- | :--- | :--- | :--- | | Results | | | | | | | Revenue | 45,108 | 49,135 | 45,541 | 49,147 | 41,713 | | (Loss) Profit for the Year | (3,382) | (3,102) | (3,590) | 4,145 | 1,362 | | Assets and Liabilities | | | | | | | Total Assets | 57,443 | 40,060 | 46,484 | 56,669 | 58,838 | | Total Liabilities | (53,248) | (32,479) | (35,885) | (42,490) | (38,847) | | Total Equity | 4,195 | 7,581 | 10,599 | 14,179 | 19,991 |